BenzoDox 60 Kit (Page 6 of 6)
REFERENCES
1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement, CLSI document M100-S23. CLSI document M100S23, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2013.
2. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Ninth Edition. CLSI document M07-A9, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2012.
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition. CLSI document M02-A11, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2012.
4. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline – Second Edition. CLSI document M45-A2, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2010.
5. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – Eighth Edition. CLSI document M11-A8, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2012.
6. Clinical and Laboratory Standards Institute (CLSI). Methods for Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard – Second Edition. CLSI document M24-A2, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2011.
7. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline. CLSI document M43-A, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2011.
8. Friedman JM and Polifka JE. Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS). Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195.
9. Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997;89:524-528.
10. Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. Int J Fertil 1980; 25:315-317.
11. Hale T. Medications and Mothers Milk. 9th edition. Amarillo, TX: Pharmasoft Publishing 2000; 225-226.
Manufactured For:
Elorac, Inc.
Vernon Hills, IL 60061
Made in the USA
Revised: 08/14, Revision 2
10-303
DOXYCYCLINE TABLETS, USP
Rx Only
Advanced Acne Wash (4.4% benzoyl peroxide extended release)
Continous Action for Lasting Results
Dermatologist Developed
3.5 FL OZ (104ml)
Drug Facts
Active Ingredient
Benzoyl peroxide 4.4%
Purpose
Acne treatment
Uses
Treats and helps prevent acne
Warnings
For external use only
Do not use if you
have very sensitive skin
are sensitive to benzoyl peroxide
When using this product
Avoid unnecessary sun exposure and use a sunscreen
Avoid contact with eyes, lips, and mouth
Avoid contact with hair and dyed fabrics, which may be bleached by this product
Skin irritation may occur, characterized by redness, burning, itching, peeling, or possibly swelling. Irritation may be reduced by using the product less frequently.
Skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time. If irritation occurs, only use one topical acne medication at a time.
Stop use and ask a doctor if
irritation becomes severe
Keep out of reach of children
If swallowed, get medical help or contact a Poison Control Center immediately.
Directions
Wet face
Apply to hands then work into a lather and massage gently onto face
Rinse thoroughly and pat dry
Because excessive drying of the skin may occur, start with one application daily, then increase to 2 times daily if needed or as directed by a doctor
If bothersome dryness or peeling occurs, reduce usage to once a day or every other day
If going outside, apply sunscreen after using this product.
If irritation or sensitivity develops, stop use of both products and ask a doctor.
Other information
THIS PRODUCT MAY BLEACH HAIR OR DYED FABRICS
KEEP TIGHTLY CLOSED
Avoid storing at temperatures above 100°F (38°C)
Inactive ingredients
Butyrospermum Parkii (Shea) Butter, C13-14 Isoparaffin, Cocamidopropyl Betaine, Ethylhexylglycerin, Euphorbia Cerifera (Candelilla) Wax, Hydroxyethyl Behenamidopropyl Dimonium Chloride, Laureth-7, Phenoxyethanol, Polyacrylamide, Water
Questions?
1-847-362-8200 MON — FRI 9 AM — 5 PM (CST)
Advanced Acne Wash
Extended — release action for lasting results
Kills bacteria that cause acne
Gentle formula
Manufactured for Elorac, Inc.
Vernon Hills, IL 60061
U.S. Patent No. 6979440
022004-2 07/2015 ©2015 Elorac, Inc.
NDC 42783-635-04
Elorac, Inc.Advanced Acne Wash
PRINCIPAL DISPLAY PANEL
NDC 42783-663-60
BenzoDox 60 Kit
Rx Only
Manufactured for: Elorac, Inc.
Vernon Hills, IL 60061
U.S. Patent No. 6979440
© Elorac, Inc.
BenzoDox™ is a trademark of Elorac, Inc.
020430
08/2015
NDC 42783-601-60
DOXYCYCLINE TABLETS, USP
100 mg
Rx Only
60 TABLETS
Manufactured for:
Elorac, Inc.Vernon Hills, IL 60061
Rev.07/15, Revision 2 10-302
NDC 42783-635-04
Advanced Acne Wash (4.4% Benzoyl Peroxide Extended Release)
Manufactured for Elorac, Inc.
Vernon Hills, IL 60061
U.S. Patent No. 6979440
022004-2 07/2015 © Elorac, Inc.
BENZODOX 60 KIT doxycycline tablets and advanced acne wash kit | ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
|
Labeler — Elorac, Inc. (832590009) |
Revised: 10/2015 Elorac, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.